The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Piper Sandler adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotech firm's stock rating from Overweight to Neutral and significantly reducing the price target to $4.00 from the ...